Humacyte, Inc.
HUMA
$2.53
$0.135.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 517.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 517.00K | -- | -- | -- | -- |
| Cost of Revenue | 15.57M | 20.66M | 22.93M | 729.00K | 21.26M |
| Gross Profit | -15.05M | -20.66M | -22.93M | -729.00K | -21.26M |
| SG&A Expenses | 8.14M | 7.43M | 7.31M | 5.75M | 5.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.70M | 28.09M | 30.23M | 29.50M | 26.58M |
| Operating Income | -23.18M | -28.09M | -30.23M | -29.50M | -26.58M |
| Income Before Tax | 39.14M | -20.94M | -39.20M | -56.66M | -31.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.14M | -20.94M | -39.20M | -56.66M | -31.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.14M | -20.94M | -39.20M | -56.66M | -31.90M |
| EBIT | -23.18M | -28.09M | -30.23M | -29.50M | -26.58M |
| EBITDA | -21.35M | -26.28M | -28.42M | -27.72M | -24.79M |
| EPS Basic | 0.28 | -0.16 | -0.33 | -0.48 | -0.29 |
| Normalized Basic EPS | -0.05 | -0.13 | -0.16 | -0.16 | -0.16 |
| EPS Diluted | 0.28 | -0.16 | -0.33 | -0.48 | -0.29 |
| Normalized Diluted EPS | -0.05 | -0.13 | -0.16 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 131.50M | 126.98M | 119.41M | 119.17M | 108.25M |
| Average Diluted Shares Outstanding | 131.76M | 126.98M | 119.41M | 119.17M | 108.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |